Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2016 16:05 ET | Source: TESARO, Inc.

Tesaro Announces Second-Quarter 2016 Operating Results

Positive Phase 3 data reported by TESARO and ENGOT from the NOVA trial of niraparib in a broad population of patients with platinum-sensitive, recurrent ovarian cancerPre-launch planning underway to...
July 21, 2016 16:05 ET | Source: TESARO, Inc.

TESARO to Announce Second-Quarter 2016 Financial Results on August 4, 2016

WALTHAM, Mass., July 21, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its second-quarter 2016 financial results on Thursday, August 4, 2016, after the close of the U.S....
July 08, 2016 16:05 ET | Source: TESARO, Inc.

ENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial

The ENGOT-OV16/NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort The ENGOT-OV16/NOVA trial successfully achieved its primary endpoint of PFS in the...
July 07, 2016 16:05 ET | Source: TESARO, Inc.

TESARO Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters

WALTHAM, Mass., July 07, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced the closing of its previously announced underwritten public offering of common stock. TESARO sold...
June 30, 2016 22:17 ET | Source: TESARO, Inc.

TESARO Announces Pricing of Public Offering of Common Stock

WALTHAM, Mass., June 30, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 4,650,000 shares of its common...
June 30, 2016 06:38 ET | Source: TESARO, Inc.

TESARO Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., June 30, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) announced today that it has commenced an underwritten public offering of $300 million of its common stock. In...
June 29, 2016 07:00 ET | Source: TESARO, Inc.

TESARO’s Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian Cancer in Both Cohorts of the Phase 3 NOVA Trial

The NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort The NOVA trial successfully achieved its primary endpoint of PFS in the non-germline...
June 23, 2016 18:30 ET | Source: TESARO, Inc.

TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer

ADELAIDE, Australia, June 23, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced nine presentations of rolapitant data at the 2016...
June 04, 2016 19:00 ET | Source: TESARO, Inc.

TESARO Provides Pipeline Update at ASCO Investor Briefing

Rolapitant IV NDA accepted for review by FDA; PDUFA date is January 11, 2017Sufficient PFS events reached for data analysis of both cohorts of Phase 3 niraparib NOVA trial; data expected in Q2...
May 19, 2016 17:45 ET | Source: TESARO, Inc.

TESARO Congratulates Dr. Mary Lynne Hedley on Being Named Life Science "Entrepreneur of the Year” by the New England Venture Capital Association

WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to congratulate co-founder, President and COO Dr. Mary Lynne...